The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; BMS Brazil; Eisai; Janssen
Consulting or Advisory Role - Astellas Pharma; Eisai; Janssen
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Merck
Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.
 
Cristina Suarez Rodriguez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech
 
Poulam Patel
Honoraria - Ipsen; Scancell Ltd.
Consulting or Advisory Role - Ipsen; Scancell Ltd.
Speakers' Bureau - BMS Brazil; Pfizer
Research Funding - Scancell Ltd.
Travel, Accommodations, Expenses - BMS Brazil; Ipsen; Merck
 
Begona Pérez Valderrama
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Novartis; Pierre Fabre
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag
 
Alejo Rodriguez-Vida
Honoraria - Astellas Pharma; AstraZeneca; Bayer; BMS Brazil; Janssen; MSD; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; BMS Brazil; Janssen; MSD; Pfizer; Roche
Research Funding - MSD (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; BMS Brazil; Clovis Oncology; Ipsen; Janssen; Novartis
 
Hilary Glen
No Relationships to Disclose
 
Fiona Thistlethwaite
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst)
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - iMatch
 
Christy Ralph
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Eisai (Inst); Merck (Inst); Roche (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen; Roche
 
Gopalakrishnan Srinivasan
No Relationships to Disclose
 
Maria Jose José Mendez Vidal
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche
 
Abigail Carter
No Relationships to Disclose
 
Charlotte Tyson
No Relationships to Disclose
 
Aaron Prendergast
No Relationships to Disclose
 
Kelly Mousa
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Thomas Powles
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech